In the early days, actually, you were pre-commercial. So what was the process in terms of gathering feedback on it? Once we put the first version of our product in the field, you're going to learn a lot from the market. And then what's important is just making sure you have open ears and you don't just go with everything you think is right.
This week, we’re super excited to have AmirAli Talasaz, co-CEO and co-founder of Guardant Health, a leading precision oncology company focused on helping conquer cancer globally.
Founded in 2011, Guardant Health is focused on helping conquer cancer through the use of its proprietary blood-based tests, vast data sets and advanced analytics. Guardant’s solutions include treatment selection, recurrence detection and early detection of cancer. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.
Through multiple rounds of private financing, Guardant Health raised over $500 million from investors including Sequoia, Khosla, Lightspeed, OrbiMed, and Softbank, and Pear! and Guardant completed a successful IPO in October 2018.